Begin main content

Frequently Asked Questions: Update of the Guidelines for the Economic Evaluation of Health Technologies: Canada

What is the current status of the Guidelines update?

CADTH began working on the Guidelines update in July 2014. After receiving feedback from users, the objectives and project scope for the Guidelines update were finalized in October 2014.

Currently, we are in the process of reviewing and updating the Guidelines. No new guidance or recommendations have been finalized at this time.

The updated Guidelines will be posted for stakeholder feedback prior to their final publication, which is anticipated for fall/winter 2016.

Will the Guidelines pertain to evaluations of different types of health care interventions?

Yes, the Guidelines are intended to provide best practices for conducting economic evaluations in Canada and aim to provide guidance applicable to all types of health care interventions, including public health interventions, drugs, and medical devices.

Will the Guidelines affect the type of information requested for CADTH Common Drug Review (CDR) and CADTH pan-Canadian Oncology Drug Review (pCODR) pharmacoeconomic submissions?

The Guidelines provide general guidance on best practices for conducting economic evaluations in Canada. Based on the Guideline recommendations, the type of information requested for CDR and pCODR pharmacoeconomic submissions may change. CADTH will communicate any procedural changes by posting updates on our website and advising stakeholders via our E-Alert service.

How can I receive alerts about this project?

To receive alerts about this project, click here to subscribe to our E-Alert and Health Economics Update mailing lists.